Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. / Frandsen, Thomas L; Abrahamsson, Jonas; Lausen, Birgitte; Vettenranta, Kim; Heyman, Mats; Behrentz, Michael; Castor, Anders; Wehner, Peder Skov; Frost, Britt-marie; Andersen, Louise Elisabeth; Schmiegelow, Kjeld.

I: British Journal of Haematology, Bind 155, Nr. 2, 2011, s. 244-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Frandsen, TL, Abrahamsson, J, Lausen, B, Vettenranta, K, Heyman, M, Behrentz, M, Castor, A, Wehner, PS, Frost, B, Andersen, LE & Schmiegelow, K 2011, 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study', British Journal of Haematology, bind 155, nr. 2, s. 244-7. https://doi.org/10.1111/j.1365-2141.2011.08835.x

APA

Frandsen, T. L., Abrahamsson, J., Lausen, B., Vettenranta, K., Heyman, M., Behrentz, M., Castor, A., Wehner, P. S., Frost, B., Andersen, L. E., & Schmiegelow, K. (2011). Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology, 155(2), 244-7. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Vancouver

Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M o.a. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology. 2011;155(2):244-7. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Author

Frandsen, Thomas L ; Abrahamsson, Jonas ; Lausen, Birgitte ; Vettenranta, Kim ; Heyman, Mats ; Behrentz, Michael ; Castor, Anders ; Wehner, Peder Skov ; Frost, Britt-marie ; Andersen, Louise Elisabeth ; Schmiegelow, Kjeld. / Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. I: British Journal of Haematology. 2011 ; Bind 155, Nr. 2. s. 244-7.

Bibtex

@article{d6b3c7d52eaf4b25a3ac9199619ac4b6,

title = "Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study",

abstract = "This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.",

author = "Frandsen, {Thomas L} and Jonas Abrahamsson and Birgitte Lausen and Kim Vettenranta and Mats Heyman and Michael Behrentz and Anders Castor and Wehner, {Peder Skov} and Britt-marie Frost and Andersen, {Louise Elisabeth} and Kjeld Schmiegelow",

note = "{\textcopyright} 2011 Blackwell Publishing Ltd.",

year = "2011",

doi = "http://dx.doi.org/10.1111/j.1365-2141.2011.08835.x",

language = "English",

volume = "155",

pages = "244--7",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

RIS

TY - JOUR

T1 - Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

AU - Frandsen, Thomas L

AU - Abrahamsson, Jonas

AU - Lausen, Birgitte

AU - Vettenranta, Kim

AU - Heyman, Mats

AU - Behrentz, Michael

AU - Castor, Anders

AU - Wehner, Peder Skov

AU - Frost, Britt-marie

AU - Andersen, Louise Elisabeth

AU - Schmiegelow, Kjeld

PY - 2011

Y1 - 2011

N2 - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

AB - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

U2 - http://dx.doi.org/10.1111/j.1365-2141.2011.08835.x

DO - http://dx.doi.org/10.1111/j.1365-2141.2011.08835.x

M3 - Journal article

VL - 155

SP - 244

EP - 247

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -

ID: 48566599